Definium Therapeutics (MMQ0) Price & Analysis

12 Followers

MMQ0 Stock Chart & Stats

€38.00

€0.60(1.60%)

At close: Jul 24 4:00 PM EDT

€38.00

€0.60(1.60%)

Day’s Range― - ―

52-Week Range€7.22 - €42.70

Previous CloseN/A

Volume30.00

Average Volume (3M)494.00

Market Cap

€5.16B

Enterprise Value€4.16K

Total Cash (Recent Filing)€1.08B

Total Debt (Recent Filing)€36.47M

Price to Earnings (P/E)―

Beta0.90

Next Earnings

Nov 05, 2026

EPS Estimate

-0.48

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-3.44

Shares Outstanding134,366,940

10 Day Avg. Volume97

30 Day Avg. Volume494

Financial Highlights & Ratios

PEG Ratio-0.19

Price to Book (P/B)3.60

Price to Sales (P/S)0.00

P/FCF Ratio-9.09

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price Target

€57.75

Price Target Upside51.98% Upside

Rating ConsensusStrong Buy

Number of Analyst Covering15

EPS Forecast (FY)-2.71

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Late-Stage Clinical ValidationPositive Phase 3 results in GAD, following earlier MDD success, strengthen evidence for DT120’s efficacy and tolerability. Repeated late-stage validation improves the probability of regulatory progress and supports potential differentiation in underserved psychiatric markets.

Liquidity And Low LeverageSubstantial liquidity and modest debt provide funding capacity for pivotal trials, regulatory work and launch preparation without immediate reliance on additional borrowing. This runway gives management flexibility to pursue key milestones before commercial revenue is available.

Broad Late-Stage PipelineMultiple indications and advanced trial programs create several potential paths to commercialization rather than dependence on one study. Breakthrough Therapy status and planned PTSD expansion may help focus development and broaden DT120’s long-term addressable opportunity.

Bears Say

No Revenue And Widening LossesDFTX remains entirely pre-commercial, with no visible revenue trajectory and materially worsening losses. Until a product is approved and launched, the business lacks operating income to offset development costs, leaving outcomes highly dependent on clinical and regulatory success.

Accelerating Cash BurnHigher spending reflects pivotal development and commercialization preparation, but it also increases the capital required before revenue begins. Sustained negative cash generation can reduce financial flexibility and create future dependence on equity financing and potential shareholder dilution.

Clinical And Regulatory Execution RiskEven with encouraging readouts, placebo effects and study-design issues could weaken confirmatory evidence. FDA requirements, safety labeling and reimbursement pathways remain unsettled, potentially delaying approval or limiting adoption and the commercial value of the pipeline.

Definium Therapeutics News

Psychedelic: Enveric, Helus, Bright Minds report earnings results

In this week’s “Psychedelic,” The Fly’s recurring series focused on psychedelic stock news, The Fly looks back on...

3d ago

LLY

ATAI

Definium Therapeutics initiated with a Buy at BofA

BofA analyst Tazeen Ahmad initiated coverage of Definium Therapeutics (DFTX) with a Buy rating and $75 price target...

6d ago

DFTX

Definium Therapeutics announces results from Phase 3 study of DT120

Definium Therapeutics (DFTX) announced positive topline results from Voyage, its first Phase 3 study of DT120 Orally Disintegrating...

6d ago

DFTX

Definium Therapeutics price target raised to $70 from $60 at Oppenheimer

Oppenheimer raised the firm’s price target on Definium Therapeutics (DFTX) to $70 from $60 and keeps an Outperform...

6d ago

DFTX

Definium Therapeutics price target raised to $66 from $50 at Needham

Needham raised the firm’s price target on Definium Therapeutics (DFTX) to $66 from $50 and keeps a Buy...

6d ago

DFTX

RBC Capital boosts Definium price target, says opportunity will be robust

RBC Capital raised the firm’s price target on Definium Therapeutics (DFTX) to $66 from $57 and keeps an...

6d ago

DFTX

Definium Therapeutics price target raised to $75 from $57 at Baird

Baird raised the firm’s price target on Definium Therapeutics (DFTX) to $75 from $57 and keeps an Outperform...

6d ago

DFTX

Definium Therapeutics price target raised to $64 from $58 at Canaccord

Canaccord analyst Sumant Kulkarni raised the firm’s price target on Definium Therapeutics (DFTX) to $64 from $58 and...

6d ago

DFTX

Definium Therapeutics price target raised to $90 from $74 at Jones

Jones raised the firm’s price target on Definium Therapeutics (DFTX) to $90 from $74 and keeps a Buy...

6d ago

DFTX

Definium Therapeutics price target raised to $66 from $57 at RBC Capital

RBC Capital raised the firm’s price target on Definium Therapeutics (DFTX) to $66 from $57 and keeps an...

6d ago

DFTX

DFTX, ANF, BBWI, DUOL, CODX: Trending By Analysts

Analysts are intrested in these 5 stocks: ( ($DFTX) ), ( ($ANF) ), ( ($BBWI) ), ( ($DUOL)...

1d ago

ANF

BBWI

Definium Therapeutics Posts Strong Phase 3 GAD Data for DT120

Definium Therapeutics ( ($DFTX) ) has issued an announcement. Definium Therapeutics reported positive topline Phase 3 results from...

5d ago

DFTX

Definium Therapeutics Issues Inducement Stock Options to New Hires

Definium Therapeutics ( ($DFTX) ) just unveiled an announcement. Definium Therapeutics has granted stock options to two newly...

5d ago

DFTX

Ami Fadia Reiterates Buy on Definium (DFTX) as Strong Phase 3 VOYAGE Data Support Unchanged $50 Price Target

Needham analyst Ami Fadia has maintained their bullish stance on DFTX stock, giving a Buy rating yesterday. Ami...

11d ago

DFTX

MMQ0 FAQ

What was Definium Therapeutics, Inc.’s price range in the past 12 months?

Definium Therapeutics, Inc. lowest stock price was €7.22 and its highest was €42.70 in the past 12 months.

What is Definium Therapeutics, Inc.’s market cap?

Definium Therapeutics, Inc.’s market cap is €5.16B.

When is Definium Therapeutics, Inc.’s upcoming earnings report date?

Definium Therapeutics, Inc.’s upcoming earnings report date is Nov 05, 2026 which is in 74 days.

How were Definium Therapeutics, Inc.’s earnings last quarter?

Definium Therapeutics, Inc. released its earnings results on Aug 06, 2026. The company reported -€1.232 earnings per share for the quarter, missing the consensus estimate of -€0.463 by -€0.769.

Is Definium Therapeutics, Inc. overvalued?

According to Wall Street analysts Definium Therapeutics, Inc.’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Definium Therapeutics, Inc. pay dividends?

Definium Therapeutics, Inc. does not currently pay dividends.

What is Definium Therapeutics, Inc.’s EPS estimate?

Definium Therapeutics, Inc.’s EPS estimate is -0.48.

How many shares outstanding does Definium Therapeutics, Inc. have?

Definium Therapeutics, Inc. has 134,366,940 shares outstanding.

What happened to Definium Therapeutics, Inc.’s price movement after its last earnings report?

Definium Therapeutics, Inc. reported an EPS of -€1.232 in its last earnings report, missing expectations of -€0.463. Following the earnings report the stock price went up 0.771%.

Which hedge fund is a major shareholder of Definium Therapeutics, Inc.?

Currently, no hedge funds are holding shares in DE:MMQ0

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Definium Therapeutics Stock Smart Score

Outperform

Fundamentals

Return on Equity

―

Trailing 12-Months

Asset Growth

319.82%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Definium Therapeutics, Inc.

Definium Therapeutics, Inc. operates as a clinical-stage biopharmaceutical firm dedicated to developing innovative therapeutic solutions for various brain health and neurological disorders. Its pipeline features key experimental drug candidates like MM120, which is currently undergoing Phase 3 clinical trials for generalized anxiety disorder (GAD) and attention deficit hyperactivity disorder (ADHD). Another significant compound, MM402 – an R-enantiomer of 3,4-methylenedioxymethamphetamine – is in Phase 1 trials, targeting the fundamental symptoms of autism spectrum disorder. The company maintains its headquarters in New York, New York.

Definium Therapeutics (MMQ0) Earnings & Revenues

Historic Earnings Reports

MMQ0 Earnings Call

Q2 2026

0:00 / 0:00

Earnings Call Sentiment|Positive

The call emphasizes strong clinical momentum (multiple Phase III programs with imminent topline readouts, Breakthrough Therapy designation in GAD, high statistical power in key studies), a clear commercialization plan and a solid cash position ($373.4M runway into 2028). These positives are tempered by materially higher operating expenses and a sizable YOY increase in net loss (driven by program investment and a non-cash warrant valuation change), design-related placebo risk from Phase II, and remaining regulatory and payer uncertainties that could affect timing and labeling. On balance, management’s message is forward-looking and execution-focused with meaningful near-term inflection points.View all DE:MMQ0 earnings summaries

MMQ0 Stock 12 Month Forecast

Average Price Target

€57.75

▲(51.98% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"6":"€6","24":"€24","42":"€42","60":"€60","78":"€78"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":77.7303432,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">€77.73</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":57.75076609599999,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">€57.75</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":45.77453544,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">€45.77</span>\n  </div></div>","useHTML":true}}],"tickPositions":[6,24,42,60,78],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Nov<br/>2025","6":"Feb<br/>2026","9":"May<br/>2026","12":"Aug<br/>2026","25":"Aug<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,37.5,40.59464178461538,43.68928356923077,46.78392535384615,49.878567138461534,52.97320892307692,56.0678507076923,59.16249249230769,62.25713427692307,65.35177606153846,68.44641784615384,71.54105963076923,74.6357014153846,{"y":77.7303432,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,37.5,39.05775123815385,40.61550247630769,42.17325371446154,43.73100495261538,45.28875619076923,46.846507428923076,48.40425866707692,49.962009905230765,51.51976114338461,53.077512381538455,54.6352636196923,56.19301485784615,{"y":57.75076609599999,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,37.5,38.13650272615384,38.77300545230769,39.409508178461536,40.046010904615386,40.68251363076923,41.31901635692308,41.95551908307692,42.59202180923077,43.228524535384615,43.865027261538465,44.50152998769231,45.13803271384616,{"y":45.77453544,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":7.18,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.8,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10.09,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":12.04,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10.53,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":11.25,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 21,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":15.88,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":14.6,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":15.65,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 31,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":17.2,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 35,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":20.4,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 47,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":42.5,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 31,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":37.5,"date":1785542400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 41,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >